Esther Rajavelu - 02 May 2025 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role: Chief Executive Officer, Chief Financial Officer and Chief Business Officer
Signature: /s/ Maegan Deare, Attorney-in-Fact for Esther Rajavelu
Issuer symbol: SPRO
Transactions as of: 02 May 2025
Net transactions value: $0
Form type: 4
Filing time: 06 May 2025, 20:01:37 UTC
Previous filing: 05 Feb 2025
Next filing: 12 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rajavelu Esther	Chief Executive Officer, Chief Financial Officer and Chief Business Officer	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE	/s/ Maegan Deare, Attorney-in-Fact for Esther Rajavelu	06 May 2025	0001903716

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SPRO	Common Stock	Award	$0	+185,000	+26%	$0.000000	909,720	02 May 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on May 2, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Chief Executive Officer, Chief Financial Officer and Chief Business Officer